Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX in advanced biliary tract cancer after gemcitabine failure
NCT02350686Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- May 2015
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in biliary tract cancer (BTC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02350686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350686.